GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Isis Pharmaceuticals, Inc. (ISIS) [hlAlert]

Rating:
Buy ISIS
up 246.97 %

Isis Pharmaceuticals, Inc. (ISIS) rated Buy

Posted on: Monday,  Sep 24, 2007  11:25 AM ET by AG Edwards

AG Edwards rated Buy Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) on 09/24/2007, when the stock price was $14.86. Since
then, Isis Pharmaceuticals, Inc. has gained 246.97% as of 11/10/2015's recent price of $51.56.
If you would have followed this AG Edwards's recommendation on ISIS, you would have gained 246.97% of your investment in 2969 days.

Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in a two principal segments: Drug Discovery and Development and Regulus Therapeutics Inc. Within the Drug Discovery and Development segment, its drug discovery platform enables the Company to identify drugs, providing potential targets to treat a range of diseases. As of December 31, 2008, the Company has 19 drugs in development. Its partners are licensed to develop, with the Company?s support, 15 of these 19 drugs. The Company and Alnylam established Regulus Therapeutics Inc. as a company focused on the discovery, development and commercialization of microRNA therapeutics. In January 2009, the Company sold its subsidiary, Ibis Biosciences, Inc. to Abbott Molecular Inc. (AMI), a wholly owned subsidiary of Abbott Laboratories.

Wachovia Corp. said it would acquire A.G. Edwards Inc. for $6.8 billion in cash and stock in a deal to form one of the largest retail stock brokerages in the United States.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2007 11:25 AM Buy
None
14.86 18.00
as of 8/27/2015
1 Week up  3.65 %
1 Month down  -19.38 %
3 Months down  -17.43 %
1 YTD up  29.41 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy